Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06836232 · ClinicalTrials.gov registry record · Phase 2

An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis

A Phase 2 study of Recurrent Pericarditis, sponsored by Zomagen Biosciences.

Recruiting
Registry status
Phase 2
Development phase
50
Enrollment target
16
Study locations

NCT06836232: Recruiting Phase 2 study of Recurrent Pericarditis, sponsored by Zomagen Biosciences.

NCT06836232 is a Phase 2 study of Recurrent Pericarditis that is actively recruiting participants, run by Zomagen Biosciences. The registered enrollment target is 50 participants, below the 214-participant average among 4 other Recurrent Pericarditis trials with a reported enrollment target (77% lower). The trial reports 16 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06836232, a Phase 2 study of Recurrent Pericarditis, is actively recruiting participants, sponsored by Zomagen Biosciences.

RECRUITING
Registry status
Phase 2
Development phase
50 participants
Enrollment target
16
Study locations

Study Summary

This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP). Cohort A will include up to 30 participants and will consist of the following: * A 30-day Screening Period (to see if a participant qualifies for the study) * A 6-week Open Label Treatment Period - participant receives VTX2735 Dose A * A 7-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose A * An 11-week Once Daily Treatment Period (if a participant meets criteria for this treatment period) - participant receives VTX2735 Dose B * A 14-day Follow-Up Period Cohort B will include up to 20 participants and will consist of the following: * A 30-day Screening Period (to see if a participant qualifies for the study) * A 6-week Open Label Treatment Period - participant receives VTX2735 Dose B or C * An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B or C * A 14-day Follow-Up Period

Primary Outcome

Incidence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to study treatment discontinuation

Conditions Studied

Recurrent Pericarditis

Interventions

  • DRUG VTX2735

Study Locations (16)

Illinois

  • Local Site #840008 - Chicago
  • Local Site #840002 - Park Ridge

Texas

  • Local Site #840019 - Houston
  • Local Site #840001 - Houston

Virginia

  • Local Site #840018 - Charlottesville
  • Local Site #840004 - Richmond

Arizona

  • Local Site #840012 - Tucson

California

  • Local Site #840014 - Orange

Florida

  • Local Site #840016 - Saint Augustine

Kentucky

  • Local Site #840011 - Owensboro

Massachusetts

  • Local Site #840010 - Boston

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-01-28
Est. Completion 2026-10
Phase Phase 2
Zomagen Biosciences

4 total trials

What NCT06836232 shows while recruiting

NCT06836232 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 214-participant average among 4 other Recurrent Pericarditis trials with a reported enrollment target (77% lower).

The record links to 1 condition, with Recurrent Pericarditis appearing as the primary indexed condition, and to 1 intervention - of which VTX2735 is the first listed.

NCT06836232 lists 16 locations in 13 states (Illinois, Texas, Virginia).

Frequently Asked Questions

What is clinical trial NCT06836232 about?

NCT06836232 is a clinical study titled "An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis". This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP). Cohort A will include up to 30 participants and will consist of the following: * A 30-day Screening Period (to see if a participant qualifies for the study) * A 6-week ...

What is the current status of trial NCT06836232?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-01-28. Estimated completion is 2026-10.

What conditions does trial NCT06836232 study?

This clinical trial studies the following conditions: Recurrent Pericarditis.

What interventions are being tested in trial NCT06836232?

The interventions under investigation include: VTX2735 (DRUG).

Who is sponsoring clinical trial NCT06836232?

This trial is sponsored by Zomagen Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06836232 being conducted?

This trial has 16 study locations across Arizona, California, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Pericarditis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06836232

Source: ClinicalTrials.gov NCT06836232, the US trial registry maintained by the National Library of Medicine. NCT06836232 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.